The performance of companies tied to the drug's legacy presents a challenging investment landscape. While the initial success generated substantial gains, generic alternatives have significantly get more info diminished revenue. Investing in connected pharmaceutical businesses now requires a thorough assessment of patent safeguards, evolving patien